Drug Profile


Alternative Names: DQ 2511; Muralis

Latest Information Update: 19 Dec 2000

Price : $50

At a glance

  • Originator Daiichi Pharmaceutical
  • Class Antisecretories; Antiulcers; Benzamides; Cytoprotectives; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Gastritis

Most Recent Events

  • 19 Dec 2000 Discontinued-preregistration for Gastritis in Japan (PO)
  • 26 May 1998 Preregistration for Gastritis in Japan (PO)
  • 16 Jan 1998 A study has been added to the therapeutic use section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top